USPTO serial 86357775
Reviewed by CopyMark Law Group
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Edmund J. Ferdinand, III
Edmund J. Ferdinand, III Meister Seelig & Fein PLLC125 Park Avenue7th FloorNew York, NY 10017| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Platform as a service (PAAS) featuring computer software platforms for use in tracking and monitoring pharmaceutical drug sales and dispensations, for use in tracking, analyzing and determining pharmaceutical drug market share, for use in tracking, analyzing and determining pharmaceutical drug co-pay distribution, for use in tracking, monitoring, analyzing and determining patient-adherence or patient-abandonment to pharmaceutical drug administration, for use in tracking, monitoring and analyzing pharmaceutical drug pricing, for use in tracking and monitoring pharmaceutical drug loss-of-exclusivity readiness, for use in evaluating, comparing and analyzing the different market performance attributes of similar pharmaceutical drugs, and for use in monitoring, tracking and reporting on the market performance of various pharmaceutical drugs throughout their respective lifecycles; Software as a service (SAAS) services featuring software for use in tracking and monitoring pharmaceutical drug sales and dispensations, for use in tracking, analyzing and determining pharmaceutical drug market share, for use in tracking, analyzing and determining pharmaceutical drug co-pay distribution, for use in tracking, monitoring, analyzing and determining patient-adherence or patient-abandonment to pharmaceutical drug administration, for use in tracking, monitoring and analyzing pharmaceutical drug pricing, for use in tracking and monitoring pharmaceutical drug loss-of-exclusivity readiness, for use in evaluating, comparing and analyzing the different market performance attributes of similar pharmaceutical drugs, and for use in monitoring, tracking and reporting on the market performance of various pharmaceutical drugs throughout their respective | SECTION 8 - CANCELLED | Mar 21, 2014 |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 10, 2025 | CAEX | CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9 | — |
| Mar 24, 2024 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Feb 1, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 1, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 1, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 30, 2021 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Jul 30, 2021 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Jul 27, 2021 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 24, 2021 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Mar 24, 2020 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Feb 4, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 4, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 3, 2016 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 3, 2016 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 2, 2016 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 2, 2016 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 29, 2015 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 24, 2015 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 6, 2015 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 6, 2015 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 17, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 3, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Nov 22, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 4, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 4, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 29, 2014 | ALIE | ASSIGNED TO LIE | — |
| Oct 27, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 23, 2014 | GEAN | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Sep 23, 2014 | GEAP | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Sep 23, 2014 | EPEN | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY | — |
| Sep 23, 2014 | CPEA | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED | — |
| Sep 16, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 14, 2014 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 8, 2014 | NWAP | NEW APPLICATION ENTERED | — |